Menu
Search
|

Menu

Close
X

Mirati Therapeutics Inc MRTX.OQ (NASDAQ Stock Exchange Global Select Market)

48.95 USD
-- (--)
As of Jul 16
chart
Previous Close 48.95
Open --
Volume --
3m Avg Volume 143,260
Today’s High --
Today’s Low --
52 Week High 54.45
52 Week Low 3.85
Shares Outstanding (mil) 31.78
Market Capitalization (mil) 1,564.96
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.88 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
9
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.510
FY17
-2.788
FY16
-4.203
FY15
-3.791
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.15
Price to Sales (TTM)
vs sector
165.31
8.04
Price to Book (MRQ)
vs sector
10.31
4.28
Price to Cash Flow (TTM)
vs sector
--
22.37
Total Debt to Equity (MRQ)
vs sector
0.00
17.43
LT Debt to Equity (MRQ)
vs sector
0.00
13.25
Return on Investment (TTM)
vs sector
-56.54
13.23
Return on Equity (TTM)
vs sector
-56.80
15.27

EXECUTIVE LEADERSHIP

Rodney Lappe
Executive Chairman of the Board, Since 2016
Salary: --
Bonus: --
Charles Baum
President, Chief Executive Officer, Director, Since 2012
Salary: $534,116.00
Bonus: --
Jamie Donadio
Chief Financial Officer, Senior Vice President, Since 2016
Salary: --
Bonus: --
Isan Chen
Chief Medical and Development Officer, Executive Vice President, Since 2013
Salary: $106,731.00
Bonus: --
Christopher LeMasters
Executive Vice President, Chief Business Officer, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

9393 Towne Centre Dr Ste 200
SAN DIEGO   CA   92121-3070

Phone: +1858.3323410

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, spectrum-selective kinase inhibitors. Both MGCD265 and MGCD516 are in development to treat patients with non-small cell lung cancer (NSCLC), and other solid tumors. MGCD265 is in Phase Ib clinical development and MGCD516 is in the dose escalation phase of Phase I clinical development. Mocetinostat is an orally-bioavailable, spectrum-selective histone deacetylase (HDAC), inhibitor, which is in Phase II development. Mocetinostat is being developed for the second line treatment of patients with bladder cancer and non-hodgkins lymphoma (NHL), specifically focusing on diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL).

SPONSORED STORIES